৳ ০.০০
আপনার সব স্বাস্থ্যসেবার সমাধান — এখন এক জায়গাতেই
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬
৳ ০.০০
১০৬৫৭
info@shukhee.com
টেলিকম ভবন, ৫৩/১, বক্স নগর, ঢাকা-১২১৬


Quantity:
Products
Payment
Delivery
Type 2 Diabetes Mellitus
Subcutaneous (SC) injection into abdomen, thigh, or upper arm
Administer once weekly, same day each week, any time of day, with or without meals
Weekly administration day can be changed if ≥48 hours between doses
Rotate injection sites within the same region each week
Adjunct to diet and exercise for glycemic control
0.25 mg SC weekly × 4 weeks → then 0.5 mg weekly
If inadequate control after ≥4 weeks at 0.5 mg, increase to 1 mg weekly
Hepatic impairment: No adjustment required
<18 years: Safety and efficacy not established
Renal impairment: No adjustment required
Personal/family history of Medullary Thyroid Carcinoma (MTC)
Patients with MEN 2
Hypersensitivity to semaglutide or components
GLP-1 agonist
Enhances glucose-dependent insulin secretion
Suppresses inappropriate glucagon secretion
Slows gastric emptying
Monitor for thyroid tumors, pancreatitis, hypoglycemia risk with insulin/sulfonylureas
>10%: Nausea, hypoglycemia (adjunctive therapy)
1–10%: Vomiting, diarrhea, abdominal pain, constipation, dyspepsia, eructation, hypoglycemia (monotherapy), flatulence, GERD
<1%: Gastritis, cholelithiasis, fatigue, dysgeusia, dizziness, injection site reaction
Limited human data; animal studies suggest fetal risk
Discontinue ≥2 months before planned pregnancy
Poorly controlled diabetes increases maternal/fetal risks
Unknown if present in human milk; detected in rat milk at lower levels
With insulin/sulfonylureas → ↑ hypoglycemia risk
Delays gastric emptying → may affect absorption of oral drugs


Indication: Type 2 Diabetes Mellitus
Administration: Subcutaneous (SC) injection — administer to abdomen, thigh, or upper arm. Inject once weekly, on the same day each week, at any time of day, with or without meals. The day of weekly administration may be changed if necessary, provided at least 48 hours have passed between doses. Use a different injection site each week when injecting in the same body region.
Adult Dose: Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Start with 0.25 mg SC weekly for 4 weeks, then increase to 0.5 mg weekly. If glycemic control is not achieved after ≥ 4 weeks on 0.5 mg, increase to 1 mg weekly. No dosage adjustment required for hepatic impairment.
Child Dose: Safety and efficacy not established (< 18 years).
Renal Dose: No dosage adjustment required for renal impairment.
Contraindication: Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). Known hypersensitivity to semaglutide or any component of the product.
Mode of Action: Glucagon‑like peptide‑1 (GLP‑1) agonist. Enhances glucose‑dependent insulin secretion, suppresses inappropriate glucagon release, and slows gastric emptying.
Precaution: Use with caution in patients with a history of pancreatitis or severe gastrointestinal disease.
Side Effects: Common (> 10%): Nausea, symptomatic hypoglycemia. Occasional (1–10%): Vomiting, diarrhea, abdominal pain, constipation, dyspepsia, eructation, flatulence, GERD. Rare (< 1%): Gastritis, cholelithiasis, fatigue, dizziness, injection‑site reaction.
Pregnancy & Lactation: Limited data in pregnant women. Potential fetal risk based on animal studies — discontinue at least 2 months before planned pregnancy.
N/A





